Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,062 across all filing types
Latest filing 2025-01-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2024
Regulatory Filings Classification · 1% confidence The document is a statutory monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Chapter 19B listing rules, detailing share capital, issued share movements, share options, etc. It is a compliance/regulatory form rather than an earnings release, annual report, or standalone share issuance announcement. It does not announce a specific financing or buyback but provides a routine listing rule return. Therefore it fits the fallback “Regulatory Filings (RNS)” category.
2025-01-03 English
CONNECTED TRANSACTION - LEASE AGREEMENT
Regulatory Filings Classification · 1% confidence The document is a Hong Kong stock exchange announcement detailing a connected transaction (lease agreement) under Chapters 14 and 14A of the HK Listing Rules. It is not a full report (e.g., annual, interim), nor earnings release, nor capital raising, nor a board change or voting result. It is an ad-hoc regulatory announcement of a transactional matter. Under the prescribed categories, it falls into the fallback “Regulatory Filings” (RNS) category for miscellaneous announcements that do not fit other specific classifications.
2024-12-24 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 1% confidence The document is an announcement enumerating the company’s board members and committee roles effective 17 December 2024, which constitutes a Board/Management Information release about director appointments and roles. This aligns with the definition of a Board/Management Information filing (MANG).
2024-12-17 English
APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER
Board/Management Information Classification · 1% confidence The document is a corporate announcement issued via the Hong Kong Exchange, titled “Appointment of Executive Director and Chief Operating Officer.” It details the board’s decision to appoint Dr. Wen Yalei as an executive director and COO, including biographical and disclosure information required under Listing Rules. This clearly falls under announcements of changes in the company’s board of directors or senior management, matching the Board/Management Information category.
2024-12-17 English
(REVISED) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2024
Regulatory Filings Classification · 1% confidence The document is HKEX Form FF301, a monthly return under Chapter 19B of the HKEX Listing Rules, detailing movements in authorised share capital, issued shares, share options and repurchases, and includes confirmations. It is a routine regulatory compliance filing to the stock exchange rather than an earnings release, proxy statement, or specific capital transaction announcement. This falls under the general category of Regulatory Filings.
2024-12-05 English
VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR CLASS II MEDICAL DEVICE OF RECOMBINANT COLLAGEN AND LAUNCH OF MEDICAL AESTHETICS PRODUCT
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement published on the Hong Kong Exchange regarding the approval of a Class II medical device and the launch of a medical aesthetics product. It contains no financial results, share transactions, dividends, board changes, proxy materials, M&A information, or other specific topics covered by the defined categories. Therefore, it falls into the general regulatory announcement category.
2024-12-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.